Piotr Desperak

Piotr Desperak

Auto-generated profile, based on publicly available information

Piotr Desperak

3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze Medical University of Silesia Katowice Poland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
JLJoanna Lewek
Joanna Lewek
JNJacek Niedziela
Jacek Niedziela
PDPiotr Desperak
Piotr Desperak
KDKrzysztof Dyrbuś
Krzysztof Dyrbuś
TOTadeusz Osadnik
Tadeusz Osadnik
Maciej BanachMaciej Banach
Maciej Banach
Background: We aimed to compare statin monotherapy and upfront combination therapy of statin and ezetimibe in patients with acute coronary syndromes (ACSs). Methods and Results: The study included consecutive patients with ACS included in the PL‐ACS (Polish Registry of Acute Coronary Syndromes), which is a national, multicenter, ongoing, prospective observational registry that is mandatory for patients with ACS hospitalized in Poland. Data were matched using the Mahalanobis distance within propensity score matching calipers. Multivariable stepwise logistic regression analysis, including all variables, was next used in propensity score matching analysis. Finally, 38 023 consecutive patients with ACS who were discharged alive were included in the analysis. After propensity score matching, 2 groups were analyzed: statin monotherapy (atorvastatin or rosuvastatin; n=768) and upfront combination therapy of statin and ezetimibe (n=768 patients). The difference in mortality between groups was significant during the follow‐up and was present at 1 (5.9% versus 3.5%; P =0.041), 2 (7.8% versus 4.3%; P =0.019), and 3 (10.2% versus 5.5%; P =0.024) years of follow‐up in favor of the upfront combination therapy, as well as for the overall period. For the treatment, rosuvastatin significantly improved prognosis compared with atorvastatin (odds ratio [OR], 0.790 [95% CI, 0.732–0.853]). Upfront combination therapy was associated with a significant reduction of all‐cause mortality in comparison with statin monotherapy (OR, 0.526 [95% CI, 0.378–0.733]), with absolute risk reduction of 4.7% after 3 years (number needed to treat=21). Conclusions: The upfront combination lipid‐lowering therapy is superior to statin monotherapy for all‐cause mortality in patients with ACS. These results suggest that in high‐risk patients, such an approach, rather than a stepwise therapy approach, should be recommended.

1 September 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
WWWojciech Wańha
Wojciech Wańha
JBJacek Bil
Jacek Bil
Rafał JanuszekRafał Januszek
Rafał Januszek
NGNatasza Gilis-Malinowska
Natasza Gilis-Malinowska
TFTomasz Figatowski
Tomasz Figatowski
WWWojciech Wojakowski
Wojciech Wojakowski
Background: Data regarding the use of percutaneous coronary intervention with drug-eluting balloons (DEB) versus thin-strut drug-eluting stents (thin-DES) for treating DES in-stent restenosis in everyday clinical practice is scarce. Our goal was to evaluate the efficacy and safety profile of DEB versus thin-DES in DES in-stent restenosis. Methods: Consecutive patients with DES in-stent restenosis who underwent percutaneous coronary intervention between 2008 and 2019 entered the multicenter DEB-DRAGON Registry with a follow-up of 3 years. Patients who received DEB at the index procedure (n=557, 49.9%) were compared with those who received thin-DES (n=560, 50.1%). Results: Analysis of the unmatched cohort revealed lower rates of target lesion revascularization (9.1% versus 13.6%; hazard ratio [HR], 0.58 [95% CI, 0.41–0.83], P =0.003), target vessel revascularization (11.8% versus 16.7%; HR, 0.62 [95% CI, 0.45–0.84], P =0.003) and device-oriented composite end point, defined as a composite of cardiac death, target lesion revascularization, and target vessel myocardial infarction (12.7% versus 16.0%; HR, 0.69 [95% CI, 0.50–0.94], P =0.018) in the thin-DES group compared with the DEB group. The incidence of cardiac death, target vessel-myocardial infarction, and myocardial infarction were similar in both groups. However, after propensity score matching, there were no significant differences in target lesion revascularization (11.2% versus 11.2%; HR, 0.91 [95% CI, 0.55–1.51], P =0.707), target vessel revascularization (13.4% versus 14.2%; HR, 0.86 [95% CI, 0.55–1.36], P =0.523), and device-oriented composite end point (14.2% versus 14.2%; HR, 0.91 [95% CI, 0.58–1.42], P =0.667) between the thin-DES and DEB group, respectively. Conclusions: This analysis of a real-life registry revealed similar long-term outcomes of thin-DES and DEB in DES in-stent restenosis regarding target lesion revascularization, myocardial infarction, cardiac death, and device-oriented composite end point. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04415216.

1 August 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
FBFrancesco Bruno
Francesco Bruno
GMGiorgio Marengo
Giorgio Marengo
OFOvidio De Filippo
Ovidio De Filippo
WWWojciech Wańha
Wojciech Wańha
SLSergio Leonardi
Sergio Leonardi
COCollaborators
Collaborators
Background: The impact of complete revascularization (CR) on the development of heart failure (HF) in patients with acute coronary syndrome and multivessel coronary artery disease undergoing percutaneous coronary intervention remains to be elucidated. Methods and Results: Consecutive patients with acute coronary syndrome with multivessel coronary artery disease from the CORALYS (Incidence and Predictors of Heart Failure After Acute Coronary Syndrome) registry were included. Incidence of first hospitalization for HF or cardiovascular death was the primary end point. Patients were stratified according to completeness of coronary revascularization. Of 14 699 patients in the CORALYS registry, 5054 presented with multivessel disease. One thousand four hundred seventy‐three (29.2%) underwent CR, while 3581 (70.8%) did not. Over 5 years follow‐up, CR was associated with a reduced incidence of the primary end point (adjusted hazard ratio [HR], 0.66 [95% CI, 0.51–0.85]), first HF hospitalization (adjusted HR, 0.67 [95% CI, 0.49–0.90]) along with all‐cause death and cardiovascular death alone (adjusted HR, 0.74 [95% CI, 0.56–0.97] and HR, 0.56 [95% CI, 0.38–0.84], respectively). The results were consistent in the propensity‐score matching population and in inverse probability treatment weighting analysis. The benefit of CR was consistent across acute coronary syndrome presentations (HR, 0.59 [95% CI, 0.39–0.89] for ST‐segment elevation myocardial infarction and HR, 0.71 [95% CI, 0.50–0.99] for non‐ST‐elevation acute coronary syndrome) and in patients with left ventricular ejection fraction >40% (HR, 0.52 [95% CI, 0.37–0.72]), while no benefit was observed in patients with left ventricular ejection fraction ≤40% (HR, 0.77 [95% CI, 0.37–1.10], P for interaction 0.04). Conclusions: CR after acute coronary syndrome reduced the risk of first hospitalization for HF and cardiovascular death, as well as first HF hospitalization, and cardiovascular and overall death both in patients with ST‐segment elevation myocardial infarction and non‐ST‐elevation acute coronary syndrome. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT 04895176.

1 January 2013 in Advances in Interventional Cardiology
Verified
Journal Article
Open access
PGPawel M. Gasior
Pawel M. Gasior
PDPiotr Desperak
Piotr Desperak
KGKarolina Gierlaszyńska
Karolina Gierlaszyńska
MHMichał Hawranek
Michał Hawranek
MGMarek Gierlotka
Marek Gierlotka
LPLech Poloński
Lech Poloński
Among patients with non-ST-elevated acute coronary syndromes (NSTE-ACS) the estimated percentage of single vessel coronary artery disease (SV-CAD) observed during coronarography is about 20-40%, while multivessel coronary artery disease (MV-CAD) is found in about 40-60%. Further treatment in...

23 January 2018 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
PTPrzemysław Trzeciak
Przemysław Trzeciak
PDPiotr Desperak
Piotr Desperak
ACAneta Ciślak
Aneta Ciślak
MHMichał Hawranek
Michał Hawranek
MGMariusz Gąsior
Mariusz Gąsior
Background: There is a paucity of data concerning young patients with stable angina (SA). Aim: The study was aimed to compare the characteristics, as well as in-hospital one, two, and five year outcomes of patients aged ≤40 and >40 years with stable angina. Methods: The analysis involved 80 patients aged ≤40 years and 9,299 patients aged >40 years with SA treated in the 3rd Department of Cardiology in Zabrze between 2006 and 2014, and enrolled in the ongoing PRESAGE Registry. Propensity scores matching was used to adjust for differences in patients’ baseline characteristics. The composite endpoint involved death, non-fatal MI, and acute coronary syndrome or ACS-driven unplanned revascularization within one, two, and five year observation period. Results: In comparison to older patients, the younger ones had a higher incidence of smoking (58.3% vs 35.2%, p<0.0001) and previous percutaneous angioplasty (45% vs 33.7%, p=0.033). There was no significant difference in in-hospital outcomes. The composite endpoint incidence did not differ significantly between the young and old group within one year (1.3% vs 8.1%, p=0.068), two years (5.8% vs 12.9%, p=0.08), and five years (23.1% vs 25.7%, p=0.71) after discharge. Young patients had a borderline lower mortality rate (0% vs 4.5%, p=0.053) after a one-year follow-up and a significantly lower mortality rate within two and five years after index hospitalization (0% vs 7.8%, p=0.02 and 5.1% vs 17.1%, p=0.04, respectively). After propensity score matching analysis, a significantly lower 2-year mortality was observed in the ≤40 age group (0% vs 8.1%; p=0.016), without significant difference in 5-year follow-up (5.1% vs 13.5%; p = 0.21). Conclusions: The younger and older group of patients with SA differed in clinical characteristics, with no significant difference in the in-hospital outcomes and composite endpoint incidence in the follow-up period. However, younger patients had a borderline lower mortality rate one year after discharge and a significantly lower mortality rate two and five years after index hospitalization. Background: There is a paucity of data concerning young patients with stable angina (SA). Aim: The study was aimed to compare the characteristics, as well as in-hospital one, two, and five year outcomes of patients aged ≤40 and >40 years with stable angina. Methods: The analysis involved 80 patients aged ≤40 years and 9,299 patients aged >40 years with SA treated in the 3rd Department of Cardiology in Zabrze between 2006 and 2014, and enrolled in the ongoing PRESAGE Registry. Propensity scores matching was used to adjust for differences in patients’ baseline characteristics. The composite endpoint involved death, non-fatal MI, and acute coronary syndrome or ACS-driven unplanned revascularization within one, two, and five year observation period. Results: In comparison to older patients, the younger ones had a higher incidence of smoking (58.3% vs 35.2%, p<0.0001) and previous percutaneous angioplasty (45% vs 33.7%, p=0.033). There was no significant difference in in-hospital outcomes. The composite endpoint incidence did not differ significantly between the young and old group within one year (1.3% vs 8.1%, p=0.068), two years (5.8% vs 12.9%, p=0.08), and five years (23.1% vs 25.7%, p=0.71) after discharge. Young patients had a borderline lower mortality rate (0% vs 4.5%, p=0.053) after a one-year follow-up and a significantly lower mortality rate within two and five years after index hospitalization (0% vs 7.8%, p=0.02 and 5.1% vs 17.1%, p=0.04, respectively). After propensity score matching analysis, a significantly lower 2-year mortality was observed in the ≤40 age group (0% vs 8.1%; p=0.016), without significant difference in 5-year follow-up (5.1% vs 13.5%; p = 0.21). Conclusions: The younger and older group of patients with SA differed in clinical characteristics, with no significant difference in the in-hospital outcomes and composite endpoint incidence in the follow-up period. However, younger patients had a borderline lower mortality rate one year after discharge and a significantly lower mortality rate two and five years after index hospitalization.

14 November 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
MTMateusz Tajstra
Mateusz Tajstra
MHMichał Hawranek
Michał Hawranek
PDPiotr Desperak
Piotr Desperak
ACAneta Ciślak
Aneta Ciślak
MGMarek Gierlotka
Marek Gierlotka
MGMariusz Gąsior
Mariusz Gąsior